Techsomed launches ‘BioTrace software suite’ for ablation therapy in the U.S.

Techsomed, a pioneering medical software company, announced the U.S. launch of its comprehensive BioTrace software suite, including the BioTraceIO Vision and BioTraceIO precision solutions. Both products received FDA clearance last year for liver tumor ablation and are now being deployed at leading medical institutions nationwide, enabling patients to access these transformative technologies.

BioTraceIO Vision employs advanced AI-based technology to deliver personalized treatment planning and assessment tools, utilising standard medical imaging to enhance the accuracy and efficiency of image-guided ablation therapy. BioTraceIO Precision, which received FDA De-Novo clearance, uses real-time ultrasound data to provide clinicians with predictive insights on post-ablation tissue damage. Importantly, both BioTraceIO Vision and BioTraceIO Precision are vendor-agnostic, seamlessly integrating with existing ablation systems and ultrasound machines to provide a streamlined workflow.

Dr. Nami Azar, Professor of Radiology at the University Hospitals Cleveland Medical said, "BioTraceIO opens new possibilities in utilizing ultrasound for image-guided liver ablation therapy. I am excited to witness its impact in action and the advancements it brings to our field".